Assessment of Cost, Morbidity, and Mortality Associated with Blood Culture Contamination
Davis KA, Painter J, Lakkad M, Dare RK
Open Forum Infectious Diseases, 6 (2): S676. October 2019.
- This is the largest known study evaluating the clinical and financial impact of blood culture contamination (BCC) with inclusion of 1,102 cases and 11,266 controls during a 5-year period.
- The study is the first reporting increased mortality associated with BCC. It also shows a correlation with increased length of stay (2 days), unnecessary exposure to antibiotics (1.3 days of treatment) and procedures, development of antibiotic-associated adverse events, and higher hospital charges.
- Clinical outcome measures were significantly higher in patients with false positive test results.
- Clinical Measure
- Vancomycin ordered
- ID consult
- In-hospital mortality
- Hospital charges
- With false positives results
- 81.3%
- 16%
- 8%
- $36,008
- With negative results
- 64.9%
- 12.9%
- 4.6%
- $28,875
- The authors concluded that the implementation of innovative strategies to reduce contamination should be pursued. Antimicrobial stewardship programs should prioritize identification of contaminants and rapid de-escalation of inappropriate antibiotics to improve patient care.